Clinical pathway of bladder cancer

Urinary bladder cancer is estimated to be the seventh most prevalent form of cancer globally, representing approximately ۳.۲% of the overall international cancer burden. Low-grade non-muscle-invasive tumors have a high recurrence rate; however, they infrequently progress to muscle invasion. In contrast, muscle-invasive tumors are typically recognized de novo and are more likely to metastasize. Ordinary clinical and pathological factors are extensively utilized for the grading and staging of tumors, as well as for forecasting the clinical results of transitional cell carcinoma. However, the prognostic capacity of these parameters is limited, and there is a paucity of indices that would enable the future assessment of risk for individual patients. In the past decade, numerous applicant biomarkers demonstrating critical pathways in carcinogenesis have been identified as clinically related and potentially beneficial as diagnostic and prognostic molecular markers, as well as prospective helpful targets. The application of molecular markers has enabled the advancement of innovative and more precise prognostic, diagnostic, and therapeutic plans. Notably, mutations in FGFR۳ and TP۵۳ have been acknowledged as significant genetic pathways involved in the carcinogenesis of transitional cell carcinoma.One of the most significant causes of hematuria is bladder cancer. Although many cases are identified through imaging techniques, cystoscopy is considered the "gold standard" for the diagnosis of bladder cancer. Numerous biomarkers identified in urine and blood samples demonstrate considerable potential for the detection and monitoring of bladder cancer. Recent trends emphasize the measurement of microRNAs (miRNAs), that regulate genes implicated in cancer development, progression, and metastasis. Metastatic bladder cancer continues to pose significant challenges due to limited treatment selections. Although various molecular alterations in the AKT /PI۳K /mTOR signaling pathway have been documented in bladder cancer, clinical trials employing small molecule inhibitors have not realized their intended outcomes. Up to now, the treatment of bladder cancer was primarily restricted to surgical interventions, chemotherapy, and immunotherapy. However, ongoing extensive analyses of molecular alterations have facilitated the development of novel therapeutic approaches. The advent of PCR and genomic hybridization techniques has enabled the investigation of alterations associated with bladder cancer at the DNA level. Recently, the examination of biological biomarkers has led to the development of more accurate diagnostic methods and targeted treatments.

کلیدواژه ها:

badder ، cancer ، pathway ، molecular ، diagnistic